Rivaroxaban (1) – Xarelto®
Prophylaxis / therapy of artherotrombotic / venothrombotic events
Characteristics
| Start date | 01.12.2013 |
|---|---|
| Resolution | 17.04.2014 |
| INN | Rivaroxaban |
| Brand name | Xarelto® |
| Pharm. company | Bayer Vital GmbH |
| G-BA Procedure ID | D-088 |
| ATC code | B01AF01 Direct factor Xa inhibitors (B01AF) |
| DDD | 20 mg O |
| Therapeutic area | Hematopoietic diseases Venous thromboembolism (VTE) |
| Reason for procedure | not completed: discontinued |
| Specialty | Patent/data protection expired |
Associated procedures
<< List of all resolutions